BioSerenity

BioSerenity — developer of solutions for individual continuous care for patients.

History

2019: Dassault Systèmes — the main investor in a financing round for 65 million euros

On June 24, 2019 it became known that the Dassault Systèmes company took part as the main investor in financing by issue of securities of series B for 65 million euros for BioSerenity. This startup is engaged in development of complete effective solutions for health care, including using the textile products equipped with sensors and also online services for diagnostics and monitoring of chronic pathologies. Three former investors – BPI, Idinvest and LBO companies also took part in the next round of investments. Dassault Systèmes will save the place in Board of Directors of BioSerenity.

The raised funds will be allocated by BioSerenity on further product development which is beyond their initial focus on cardiovascular diseases, neurologic diseases and sleep disorders and will help the company to continue business development at the international level and also to propose solutions for telemedicine.

The BioSerenity company founded in 2014 with the headquarters in Paris is Part 3DExperience Lab and is engaged in development of wearable medical devices and digital solutions for patient care in which innovations in textiles, artificial intelligence, electronic information collection systems from patients (ePRO), Internet of Things and cloud computing are applied.

The startup offers medical institutions and doctors of a portfolio of full-function services of health care. Besides, BioSerenity provides to the pharmaceutical companies ready-made solutions for the accompanying diagnostics. Similar complex approach allows the medical organizations to increase the efficiency and to reduce costs, to patients helps to receive quicker the exact diagnosis, and to specialists – to appoint treatment and to carry out therapy using collecting of clinical data and information on the patient's status.

Development of the industry of health care will be based on distribution of the medical devices connected to network allowing to obtain economically and continuously state-of-health data of patients, providing their comfort and observance of treatment. In turn to medical community such approach allows to diagnose and treat diseases at an early stage that contributes to the development of the health care focused on result. It also is the main mission of BioSerenity. For many years Dassault Systèmes invests in creation of the first complex platform for joint work which is intended to accelerate innovations in the medicobiological industry for implementation the patient - the focused approach to treatment, told Claire Biot, the vice president for Dassault Systèmes biotechnologies

Thanks to the next round of financing we not only receive means for continuation of our growth, but also we strengthen our partnership with Dassault Systèmes, the company in vanguard of innovations in health care, noted Pierre-Yves Frouin, the president of BioSerenity